Do polyamines play a role in the pathogenesis of the anemia of end-stage renal disease?  by Kushner, David S. et al.
Kidney International, Vol. 36 (1989), pp. 171—1 74
EDITORIAL REVIEW
Do polyamines play a role in the pathogenesis of the anemia of
end-stage renal disease?
A normochromic normocytic anemia with a hypoproliferative
bone marrow is invariably associated with the latter stages of
end-stage renal disease (ESRD) [1—31, and has been the focus of
much research over the past few years. The anemia of ESRD is
multifactorial in origin. Possible causes of this anemia include
erythropoietin deficiency, [41 hemolysis [51 and blood loss from
various causes including chronic dialysis [6—8], inhibitors of
erythropoiesis [9—111, and poor nutritional status [12].
Two major factors have been implicated in the pathogenesis
of the anemia of ESRD. First and foremost, there is a deficiency
of erythropoietin production in ESRD, in that serum erythro-
poietin concentrations, although often found to be normal [9,
13] or elevated [10, 13], may not be high enough relative to the
severity of the anemia [4]. Secondly, polyamines, which are
organic cations that play various roles in normal cellular prolif-
eration and differentiation [14—17], accumulate in plasma and
body fluids of patients suffering from ESRD [181, and have been
reported to reduce the proliferation and maturation of erythroid
cells [11—121. However, the relative role of polyamines in this
anemia is controversial.
A review of the anemia of ESRD appeared in this journal in
1985 emphasizing the role of Ep deficiency as the primary
etiology of this disease [19]. The purpose of this paper is to
review current knowledge regarding this anemia, and to con-
sider the question, do polyamines play any role in the patho-
genesis of the anemia of ESRD? The reason for considering this
question is that even though erythropoietin levels in plasma are
normal or elevated, the uremic patient in ESRD remains
anemic. These plasma erythropoietin levels in uremic patients
with anemia, although elevated, are low for the degree of
anemia when compared with plasma Ep levels in patients with
sickle cell or iron deficiency anemias (Fig. 1) [20]. However,
improvement in the anemia has been reported with the use of
continuous ambulatory peritoneal dialysis [21—23]. This sug-
gests the existence of dialyzable substances present in the sera
of uremic patients that act as inhibitors of erythropoiesis. These
substances could be polyamines. There are three major areas of
controversy regarding the role of polyamines in this anemia.
First, are levels of polyamines significantly elevated in the sera
of uremic patients, and if so, is there a correlation between the
degree of uremia and anemia with serum levels of the poly-
amines? Secondly, do polyamines exert a specific inhibitory
effect on erythropoiesis, or do they exert a generalized nonspe-
cific cellular surpressive effect disrupting both myelopoiesis and
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erythropoiesis? Finally, do polyamines contribute to the anemia
of ESRD by inhibiting the bioactivity of erythropoietin itself?
The first controversial point to be addressed is whether
polyamines accumulate in the plasma and body fluids of pa-
tients suffering from ESRD. Crucial to establishing a role for
polyamines in the pathogenesis of the anemia of ESRD is the
demonstration of elevated levels of polyamines in the sera of
uremic patients as well as a correlation between polyamine
levels with the degree of uremia and anemia. Several studies
[18, 24—26] have demonstrated elevated levels of polyamines in
uremia. Swendseid, Panaqua and Kopple [25] using an amino
acid analysis technique reported elevated levels of free sper-
mine and spermidine in erythrocytes, and increased putrescine
in the urine of patients in renal failure. These investigators [25]
postulated that an increase in polyamines in blood was involved
in the mechanism of the anemia of ESRD. Similarly, using a
radioimmunoassay technique Campbell et al [24] reported that
the polyamines spermine and spermidine were increased up to
six times normal levels in the sera of patients with renal failure
and on regular hemodialysis. However, the values reported by
this group [24] were obtained by a radioimmunoassay method
which may not be specific since the spermine antibody em-
ployed in this study could have a 22% cross reactivity with
spermidine. Even though the validity of this work was ques-
tioned [27], and this radioimmunoassay may not have been
specific for spermine, it is still possible that the assay did detect
polyamines as a class. In contrast to the results obtained in this
study [24], Spragg and Hutchings [26] using high performance
liquid chromatographic analysis of the predialysis sera of nine
anemic and severely uremic patients, found only serum pu-
trescine levels to be elevated to two times that of normal values,
while spermine and spermidine levels were not increased.
Conversely, Saito et al [18] also using high-performance liquid
chromatography and the same fluorometric technique, with a
five times larger sample population, found a statistically signif-
icant elevation in serum levels of the polyamines, cadaverine,
putrescine, spermine, and spermidine in the sera of uremic
patients. In addition, spermine levels have been shown to be
reciprocally correlated with hematocrit values in patients suf-
fering from anemia of ESRD [18]. These investigators [18] have
also reported a significant correlation between the increase in
serum creatinine and the elevations in serum spermidine and
putrescine in patients with ESRD. Thus, these reports demon-
strate that serum levels of polyamines are elevated in ESRD,
and there appears to be a correlation between the levels of some
polyamines with the degree of anemia and uremia. It would be
interesting to determine with the use of multiple linear regres-
sion analysis, as was done with PTH in similar studies [28],
whether, after controlling for the effect of creatinine, the








o Q0 O09O 0 000
Aol 01 I I
0 15 20 25 30 35 40 45
Hematocrit, %
Fig. 1. Relationship between serum erythropoietin concentration and
hematocrit levels in children with normal renal function and varying
degrees of anemia due to sickle cell disease or iron deficiency (•), in
children with end-stage renal disease (ESRD) (0) and in anephric
children (tx), The mean serum Ep levels in 35 children with ESRD was
32.4 2.4 iJml; 30 children with anemia of similar severity with sickle
cell disease or iron deficiency ranged between 28.7 to 327 Ep/ml; the
mean serum Ep titers in 4 anephric children was 9.1 0.75 Jml; the
mean for 20 normal children was 19.6 1.5 imi. Used with permission
from Textbook of Nephrology [20]. Based on data from fLab C/in Med
105:449—458, 1985 [35].
polyamines are a significant predictor of hematocrit in patients
with anemia and uremia in ESRD.
The second controversial point to be addressed is whether or
not elevated levels of polyamines exert a specific inhibitory
effect on erythropoiesis. Since a normochromic-normocytic
anemia is characteristic of ESRD, whereas leukopenia or a
generalized myelosuppression is not typical, it is essential to
establish that polyamines are specific inhibitors of erythropoie-
sis. Evidence in support of polyamines exerting an erythroid-
specific inhibitory effect comes from the work of several
investigators [29—32]. Radtke et al [11] first reported that
spermine was an inhibitor of erythropoiesis using a fetal mouse
liver erythroid colony system. Recently it has been shown that
the polyamines, spermine, and spermidine are potent inhibitors
of erythropoietin-stimulated incorporation of 59Fe into newly
synthesized heme by fetal mouse liver cells in short-term
culture, suggesting one possible mechanism by which the
polyamines may exert an erythroid-specific inhibitory effect
[29].
It is known that the anemia of ESRD progresses in the course
of renal insufficiency to the point where dialysis becomes
necessary [9, 21—29, 331 and then the anemia improves after
several weeks of adequate dialysis therapy [8, 13]. Since it has
already been shown that polyamine levels are elevated in the
sera of uremic patients, it should stand to reason that if
polyamines are pathogenic in the anemia of ESRD, then the
sera of uremic patients should inhibit erythropoiesis to a greater
extent than granulopoiesis if tested in vitro in bone marrow
cultures. We have recently demonstrated that sera of predialy-
sis uremic patients exert a more selective dose-related inhibi-
tion of erythroid colony formation than of granulocyte-mac-
rophage colony growth in murine bone marrow cultures [31].
Similarly, recent work using sera from uremic patients and
ABO-matched human bone marrow cultures showed a selective
inhibition of erythropoiesis; albeit, a stimulatory effect on
granulopoiesis was reported [30]. This finding is in accord with
previous observations that the sera of uremic patients may
support granulopoiesis more efficiently than sera from normal
subjects [34, 35]. In contrast, Delwiche et al [36] found that sera
from uremic patients lacked in vitro specificity. In comparison
with normal human serum, increasing concentrations of sera
from uremic patients induced inhibition of the growth of eryth-
roid (CFU-E), granulocyte-macrophage (CFU-GM) and mega-
karyocytic (CFU-Meg) colonies [36]. However, Pavlovic-Ken-0o tera [37], also using the mouse bone marrow erythroid colony
(CFU-E) assay, reported inhibition of CFU-E colony formation
in 34 of 35 hemodialysis patients with ESRD. None of the sera
of these ESRD patients produced a significant inhibition of
CFU-GM [37]. Also, it is worth noting that a transient neutro-
penia regularly develops in some patients with ESRD undergo-
ing hemodialysis [38]. However, studies of the pathogenesis of
this phenomenon suggests that this decrease in blood levels of
neutrophils and monocytes is due to sequestration of these cells
in the pulmonary vasculature of the dialysis patient. It has been
suggested [381 that this neutropenia results from the activation
of complement by the dialysis coil. There are no reports of a
suppression of leukopoiesis in patients with ESRD caused by
specific uremic toxins.
Spermine and spermidine were recently found to inhibit
erythropoiesis to a greater extent than granulopoiesis in a
dose-related manner [32]. This work is in contrast to the
findings of Segal, Stueve and Adamson [39], who reported that
these polyamines lacked in vitro specificity. The reason for this
discrepancy is not known, however, differences may exist in
culture technique. One notable difference is that although both
groups used greater than physiological concentrations of poly-
amines, Kushner et al [321 used a tenfold greater concentration
of polyamines at their highest test dose. Even at this high
concentration of polyamines neither erythroid nor granulocyte-
macrophage colony growth was totally eliminated. In contrast,
Segal, Stueve and Adamson [39] showed a complete elimination
of both erythroid and granulocytic-macrophage colony growth
at a polyamine concentration thirty times lower than the peak
concentration used by Kushner et al [32]. The reasons for these
differences are not known. Further work is needed to defini-
tively establish whether or not the polyamines as a group, or
one polyamine in particular, exerts an inhibitory effect specifi-
cally on erythropoiesis.
Finally, in considering mechanisms for the polyamines in the
pathogenesis of the anemia of ESRD, if indeed they are
involved in the mechanism of this anemia, an interaction
between the polyamines and erythropoietin at the level of the
bone marrow is possible. For example, as mentioned previously
it has recently been shown that the polyamines spermine and
spermidine are among the most potent inhibitors of erythropoi-
etin-stimulated incorporation of 59Fe into newly synthesized
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suggesting a possible pathogenic mechanism. However, it is not
clear whether this inhibition of polyamines on 59Fe incorpora-
tion into heme is due to an effect directly on Ep, erythroid cells
or heme synthesis itself. It seems clear that inadequate produc-
tion of erythropoietin by the diseased kidney is a major con-
tributing factor to the anemia of uremia [4, 10, 13, 40, 41]. In
addition, it has been suggested that the most important factor
leading to the anemia of ESRD is a dysregulation of erythro-
poietin synthesis in response to anemic hypoxia [4]. In contrast,
it has been shown that the anemia of ESRD progresses in the
course of renal failure to the point where dialysis becomes
necessary [9], and then the anemia improves after several
weeks of adequate dialysis therapy [33]. Improvement of the
anemia has been demonstrated in patients on dialysis despite a
significant drop in serum erythropoietin concentrations [9, 33],
while at the same time there is an increase in hemoglobin
concentration [33]. Also, in an early report only 2 of 16 patients
with advanced renal disease on dialysis therapy for as long as
six years had higher than normal Ep levels when the sera were
assayed in hypoxic protein-starved mice [42]. However, more
recently it has been shown that serum erythropoietin levels in
uremic patients, although inappropriately low for the degree of
anemia, are often above the levels present in normal nonanemic
individuals [33, 43, 44]. These observations provide indirect
support for a pathogenic role of inhibitors or toxic factors which
inactivate erythropoietin, and which accumulate in the sera of
uremic patients during the course of ESRD, which are re-
moved, at least in part, by dialysis therapy. Further support for
this hypothesis comes from three recent reports on the effects
of different modes of dialysis on serum erythropoietin levels
[22, 45, 46]. In these studies [22, 45, 46] as in previous work [21,
231, higher post-dialysis hematocrits and erythropoietin levels
were seen with continuous ambulatory peritoneal dialysis than
with hemodialysis, suggesting that more efficient modes of
dialysis effectively remove some substance or substances that
accumulate in the sera of uremic patients which reduce both the
immunologic and biologic activity of erythropoietin. Similarly
using a radioimmunoassay technique, McGonigle et al [35]
demonstrated that the sera of normal human subjects were
capable of enhancing the immunoreactivity of human urinary
erythropoietin, whereas sera from uremic patients either failed
to enhance or slightly reduced the immunoreactivity of Ep.
Also, in this report the sera of uremic patients incubated with
Ep were shown to block its biological reactivity in a fetal mouse
liver erythroid colony assay. However, it is not clear whether
the inhibition was due to the inactivation of Ep itself or was the
result of inhibition of the effects of Ep on erythroid colony
formation at the cellular level. It has been shown that a dose
responsive increase in hematocrit level can be induced in
patients with the anemia of ESRD with the administration of
increasing concentrations of purified human recombinant Ep
[47]. However, the plasma levels of Ep in dialysis patients
treated with human recombinant Ep to maintain a normal
hematocrit are well above physiological levels [48]. Thus, this
may indicate that a competitive inhibition of the effects of Ep on
hematocrit can be overcome by elevated levels of this hormone,
and support the existence of circulating uremic toxins which
either inactivate Ep directly or block its effect at a cellular level.
Overall, there is considerable support in favor of substances
accumulating in the sera of uremic patients which may interact
with erythropoietin leading to anemia in ESRD, but there is no
direct evidence that these substances are polyamines. How-
ever, there is strong indirect support for implicating the poiy-
amines as uremic toxins. Further work is necessary to defini-
tively determine if a specific role for polyamines exists in the
mechanism of this anemia.
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